The Risk and Natural Course of Age-Related Maculopathy: Follow-up at 6½ Years in the Rotterdam Study
Abstract
OBJECTIVES: To evaluate the natural course of age-related maculopathy (ARM) and to assess the incidence and absolute risk of its final stage, age-related macular degeneration (AMD). METHODS: In a population-based prospective cohort study of 6418 persons 55 years and older, we studied the incidence and natural course of ARM. Subjects underwent identical examinations, including stereoscopic fundus photography, at baseline and at 2.0 and 6(1/2) years' follow-up. Age-related maculopathy was graded according to the International Classification and Grading System for ARM and AMD, and stratified into 5 exclusive stages. Incidence was expressed in rates and 5-year absolute risks. RESULTS: At follow-up, 47 new cases of AMD were identified, with a ratio of neovascular-atrophic AMD of 1.4:1. The 5-year risk of AMD increased with more severe stages to 28.0% for subjects 55 years and older with indistinct drusen and pigmentary irregularities (stage 3). Age, but not sex, independently increased this risk to a maximum of 42.0% for subjects with stage 3 ARM who were 80 years and older. Individual ARM fundus signs that predicted best the development of AMD were 10 or more large drusen (> or =125 microm) and 10% or more of the grid area covered by drusen. Subjects who developed atrophic AMD showed no significant (P =.25) differences in baseline fundus signs and natural course compared with subjects who developed neovascular AMD. CONCLUSIONS: We provided the absolute risk of AMD as a function of age and early ARM fundus signs, and showed that both are prominent independent risk factors. The progression of ARM stages follows, after the appearance of the first soft drusen, a distinct course at a gradual pace that accelerates with increasing age.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The 5-year progression rate to advanced age-related macular degeneration in individuals who had intermediate age-related macular degeneration and who were 80 years or older was 42% in the Rotterdam Study.
“The 5-year progression rate to advanced age-related macular degeneration in individuals who had intermediate age-related macular degeneration and who were 80 years or older was 42% in the Rotterdam Study.20”
From Age-related macular degeneration (2008) · cites this paper as [20]
The citation lists haven’t been fetched yet
References 30 · Cited by 332
- Authors
- van Leeuwen, R.
- Venue
- Archives of Ophthalmology
- Publisher
- American Medical Association (AMA)
- Published
- 2003-04-01
- Volume
- 121
- Issue
- 4
- Pages
- 519
- ISSN
- 0003-9950 (ISSN-L)
- OpenAlex
- W2158770960
- Cited by
- 332
- References
- 30
- Citations by year
- 2026: 6 · 2025: 4 · 2024: 9 · 2023: 6 · 2022: 7 · 2021: 12 · 2020: 12 · 2019: 6 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 10 · 2014: 19 · 2013: 21 · 2012: 27
- FWCI
- 23.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- age-related maculopathy, age-related macular degeneration, natural history (disease), incidence, absolute risk, drusen, neovascular AMD, atrophic AMD, disease progression, risk factors, aging
- MeSH terms
- Age Factors, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Macular Degeneration, Male, Middle Aged, Netherlands, Prospective Studies, Risk Factors, Incidence, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review